MacroGenics Inc
Change company Symbol lookup
Select an option...
MGNX MacroGenics Inc
CBZ CBIZ Inc
PSEC Prospect Capital Corp
SPEC Spectralcast Inc
RC Ready Capital Corp
GNK Genco Shipping & Trading Ltd
NVOS Novo Integrated Sciences Inc
PDRDF Pernod Ricard SA
RKDA Arcadia Biosciences Inc
BBVA Banco Bilbao Vizcaya Argentaria SA
Go

Health Care : Biotechnology | Small Cap Value

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Closing Price: $3.98

Day's Change: 0.08 (2.05%)

Bid: --

Ask: --

B/A Size: --

Day's High: 4.15

Day's Low: 3.79

Volume (Below Average) Volume: 815,561 10-day average volume: 1,005,652: 815,561

Berkshire Hathaway Inc. Cl B Stock Rises Tuesday, Still Underperforms Market

4:41 pm ET December 21, 2021 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Berkshire Hathaway Inc. Cl B (BRKA) advanced 1.25% to $293.24 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 1.78% to 4,649.23 and the Dow Jones Industrial Average rising 1.60% to 35,492.70. The stock's rise snapped a two-day losing streak. Berkshire Hathaway Inc. Cl B closed $8.34 below its 52-week high ($301.58), which the company reached on December 16th.

Trading volume (3.9 M) remained 398,840 below its 50-day average volume of 4.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled December 21, 2021.

-MarketWatch Automation

(END) Dow Jones Newswires

December 21, 2021 16:41 ET (21:41 GMT)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and